Tamares to upgrade hotels

Over recent years, the hotel group has invested a total of NIS 200m. in expanding in presence in the Israeli hotel industry, including the acquisition of the Golden Tulip and the Shizen Spa hotels.

By SHARON WROBEL
August 21, 2007 08:15

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later

The Tamares Hotels Resorts and Spas group said Monday it plans to invest an additional NIS 30 million in revamping the Daniel hotels in Herzliya and the Dead Sea over the next three years. Over recent years, the hotel group has invested a total of NIS 200m. in expanding in presence in the Israeli hotel industry, including the acquisition of the Golden Tulip and the Shizen Spa hotels. Tamares, a privately owned investment company based in Vaduz, Lichtenstein has interests in real estate, finance, media and leisure

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS